Granted Patent
B2
US 12,350,247 · App. 18/295,907 · Granted Jul 8, 2025
Use of APE1/Ref-1 inhibitors for treatment of retinal diseases
A61K31/201A61K31/165A61K31/18A61K31/192A61K31/20A61K31/282A61K31/337A61K31/343A61K31/501A61K31/519A61K31/7068A61K31/713A61K33/243A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).
Claims (7)
1. A method of treating retinopathy of prematurity (ROP) in a subject in need thereof, the method comprising administering to the subject [(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide] (APX2009).
2. The method as set forth in claim 1 further comprising administering a second therapeutic agent.
3. The method as set forth in claim 2 , wherein the second therapeutic agent is selected from the group consisting of doxorubicin, endostatin, 5-fluorouracil (5-FU), bortezomib, ispinesib mesylate, SN-38, topotecan, paclitaxel, bryostatin 1, trametinib, LAQ824, vinblastine, BEZ235, panobinostat, methotrexate, temsirolimus, FK866, afatinib, tozasertib, irinotecan, GSK2126458, CPI-613, γ-secretase inhibitors, DLL4-inhibiting antibodies, and combinations thereof.
4. A method of treating neovascularization in a subject in need thereof, the method comprising administering to the subject [(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide] (APX2009).
5. The method as set forth in claim 4 , wherein the neovascularization is selected from the group consisting of retinal neovascularization and choroidal neovascularization (CNV).
6. The method as set forth in claim 4 further comprising administering a second therapeutic agent.
7. The method as set forth in claim 6 , wherein the second therapeutic agent is selected from the group consisting of doxorubicin, endostatin, 5-fluorouracil (5-FU), bortezomib, ispinesib mesylate, SN-38, topotecan, paclitaxel, bryostatin 1, trametinib, LAQ824, vinblastine, BEZ235, panobinostat, methotrexate, temsirolimus, FK866, afatinib, tozasertib, irinotecan, GSK2126458, CPI-613, γ-secretase inhibitors, DLL4-inhibiting antibodies, and combinations thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 5, 2023
From: KELLEY, MARK R.; FISHEL, MELISSA L.
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 063227/0650 →
Continuity (5)
Continuation
16092812
Provisional Application
62521082
· Jun 16, 2017
Provisional Application
62473528
· Mar 20, 2017
References Cited (53)
US 9040505B2
· Kelley
· 2015
[cited by examiner]
US 9315481B2
· Kelley
· 2016
[cited by examiner]
US 20030229004A1
· Zarling
· 2003
[cited by examiner]
CA 2700274A1
· 2009
[cited by applicant]
JP 2014516051A
· 2014
[cited by applicant]
WO 2012162589A1
· 2012
[cited by applicant]
WO 2014047782A1
· 2014
[cited by applicant]
Mark R. Kelley, James H. Wikel et al. Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy, Journal…
[cited by examiner]
Y. Li , X. Liu , T.Zhou , M.R. Kelley , P. Edwards , H. Gao , X.Qiao, Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization…
[cited by examiner]
Arpin et al., Applying Small Molecule Signal Transducer and Activator of Transcriptson-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics; 2016, Molecular Cancer Therapeutics, vol. 15, No. 5, pp. 794-805.
[cited by applicant]
Blum et al., Systemic Inflammation Alters Satellite Glial Cell Function and Structure. A Possible Contribution to Pain; Neuroscience, 2014, vol. 274, pp. 209-217.
[cited by applicant]
Brooks et al., DNA repair in neural cells: basic science and clinical implications; 2002, Mutation Research, vol. 509, pp. 93-108.
[cited by applicant]
Cardoso et al., Metagenomic Analysis of the Microbiota from the Crop of an Invasive Snail Reveals a Rich Reservoir of Novel Genes; PLOS One, 2012, vol. 7, No. 11, e48505.
[cited by applicant]
Chen et al., Peptidase Inhibitors Improve Recovery of Substance P and Calcitonin Gene-Related Peptide Release From Rat Spinal Cord Slices; Peptides, vol. 17, No. 1, pp. 31-37.
[cited by applicant]
Chen et al., Inhibition of Carbonic Anhydrase-IX as a Novel Strategy to Overcome Hypoxia Mediated Drug Resistance in FLT3/ITD Mutated Acute Myeloid Leukemia; Blood, 2017, 1-page.
[cited by applicant]
Fishel et al., Impact of APE1/Ref-1 Redox Inhibition of Pancreatic Tumor Growth; Mol Cancer Ther., 2011, vol. 10, No. 9, pp. 1698-1708.
[cited by applicant]
Kelley et al., Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy; The Journal of Pharmacology an…
[cited by applicant]
Kelley et al., Challenges and opportunities identifying therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from oxidative DNA damage; Neural Regen Res., 2017, vol. 12, No. 1, pp. 72-74.
[cited by applicant]
Konig et al., Inhibition of Carbonic Anhydrase IX as a Novel Strategy to Target FLT3/ITD Mutated AML Cells Under Hypoxic Conditions; Poster Presentations; Experimental Hematology, 2017, vol. 53, pp. S54-S136.
[cited by applicant]
Kramer et al., Causal analysis approaches in Ingenuity Pathways Analysis; Bioinformatics, 2014, pp. 1-8.
[cited by applicant]
Lindblom et al., Tesalitazar, a Dual PPAR-α/γ Agonist, Hamster Carcinogenicity, Investigative Animal and Clinical Studies; Toxicologic Pathology, 2012, vol. 40, pp. 18-32.
[cited by applicant]
Logsdon et al., Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression; Dual-Targeting in Patient-Derived 3D Pancreatic Cancer Models; American Association for Cancer Research; 33-pages.
[cited by applicant]
Masood et al., Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy; Cancers, 2011, vol. 3, pp. 1527-1549.
[cited by applicant]
Mcelyea e al., Abstract 5183: Efficacy study of APX3330, a Ref-1 redox inhibitor, and Gemcitabine in a mouse pancreatic ductal adenocarcinoma model; Cancer Research, Tumor Biology; 4-pages.
[cited by applicant]
McHugh M.L, Multiple comparison analysis testing in Anova; Lessons in Biostatistics; 2011, Biochemia Medica, vol. 21, No. 3, pp. 203-209.
[cited by applicant]
Ren et al., Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathwa…
[cited by applicant]
Sempere et al., A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells; Cancer Biology & Therapy; vol. 12, No. 3; 2011, pp. 198-207.
[cited by applicant]
Shah et al., Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic; Precision Oncology; 19-pages.
[cited by applicant]
Stevens et al., A comparison of multiple testing adjustment methods with block-correlation positively-dependent tests; PLOS/ONE; 12-pages.
[cited by applicant]
Su et al., Interactions of APE1 with a redox inhibitor: Evidence for an alternate conformation of the enzyme; Biochemistry, 2011, vol. 50, No. 1, pp. 82-92.
[cited by applicant]
Zhang et al., Inhibition of Apurinic/Apyrimidinic Endonuclease I's Redox Activity Revisited; Biochemistry; 2013; vol. 52, pp. 2955-2966.
[cited by applicant]
WPI Database, 2017, Clarivate Analytics, 2-pages.
[cited by applicant]
Lou et al., Aberrant expression of redox protein Ape1 in colon cancer stem cells; Oncology Letters, 2014, vol. 7, pp. 1078-1082.
[cited by applicant]
Opydo-Chanek et al., Combined action of obatoclax and resveratrol on MOLT-4 cells; Department of Experimntal Hematology, Jagiellonian University in Krakow; 1-page.
[cited by applicant]
Suzuki et al., Drug-induced Apoptosis and p53, BCL-2 and BAX Expression in Breast Cancer Tissues in Vivo and in Fibroblast Cells in Vitro; Jpn J Clin Oncol, 1999, vol. 29, No. 7, pp. 323-331.
[cited by applicant]
Yang et al., Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibito…
[cited by applicant]
Zhang et al., Inhibition of Apurinic/apyrimidinic endonuclease I's redox activity revisited; Biochemistry, 2013, vol. 52, No. 17, pp. 2955-2966.
[cited by applicant]
Bray et al., Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer; Mol. Cancer Res, 2009, 11-pages.
[cited by applicant]
Luo et al., Inhibition of the human apurinic/apyrimidinic endonuclease DNA base excision repair enzyme/redox factor (APE1/Ref-1) using small molecule redox and repair inhibitors: Therapeutic implications; Experimental a…
[cited by applicant]
Li et al., Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization, Jan. 2014, Redox Biology; vol. 2, pp. 485-494.
[cited by applicant]
Gampala et al., Ref-1 redox activity allers cancer cell metabolism in pancreatic cancer: Exploiting the novel finding as a potential target; J. Exp. Clin. Cancer Res., Aug. 2021, vol. 40, No. 1, pp. 251.
[cited by applicant]
Hartman et al., Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy, Int. J. Mol. Sci., Oct. 2021, vol. 22, No. 19, pp. 10279.
[cited by applicant]
Kelley et al., Functional Analysis of Novel Analogues of E3330 That Block the Redox Signaling Activity of the Multifunctional AP Endonuclease/Redox Signaling Enzyme APEZ1/Ref-1, Antioxidants & Redox Signaling, 2011, vol…
[cited by applicant]
Logsdon et al., Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival; Sci. Rep., 2018, vol. 8, pp. 13759.
[cited by applicant]
Luo et al., Role of the multifunctional DNA repair and redox signaling protein APE1/Ref-1 in cancer and endothelial cells: Small-molecule inhibition of the redox function of APE1. Redox Signal, 2008, vol. 10, pp. 1853-1…
[cited by applicant]
Nyland et al., Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1). J. Med. Chem., 2010, vol. 53, pp. 1200-1210.
[cited by applicant]
Pasha et al., Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovasclariztion, J. Pharmacol., Exp. Ther., 2018, vol. 367, No. 1., pp. 108-118.
[cited by applicant]
Jiang et al., Inhibition of APE1/Ref-1 redox activity with ZPX3330 blocks retinal angiogenesis in vitor and in vivo. Vision Research, 2011, vol. 51, pp. 93-100.
[cited by applicant]